FDA Approves Tzield for Pediatric Type 1 Diabetes Patients Ages 8-17

The FDA granted accelerated approval to Tzield (teplizumab) on June 12, 2026, for a new indication to delay insulin production decline in pediatric patients aged 8-17 with recently diagnosed Stage 3 type 1 diabetes. The approval expands the drug's use to a younger patient population with early-stage disease.